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Abstract. Akt1/protein kinase Bα (Akt1/PKBα) is a down-
stream mediator of the insulin signaling system. In this study 
we explored mechanism(s) for its role in burn injury. Akt1/
PKBα in liver extracts from mice with burn injury fed with 
(2H7)-L-Leu was immunoprecipitated and isolated with 
SDS-PAGE. Two tryptic peptides, one in the kinase loop and 
a control peptide just outside of the loop were sequenced via 
nano-LC interfaced with quadruple time-of-flight tandem 
mass spectrometry (Q-TOF tandem MS). Their relative 
isotopologue abundances were determined by stable isotope 
labeling by amino acids in mammalians (SILAM). Relative 
quantifications based on paired heavy/light peptides were 
obtained in 3 steps. The first step included homogenization 
of mixtures of equal amounts of tissue from burned and 
sham-treated animals (i.e., isotope dilution) and acquisition of 
uncorrected data based on parent monoisotopic MS ion ratios. 
The second step included determination of isotopic enrich-
ment of the kinase from burned mice on Day 7 and the third 
step enrichment correction of partially labeled heavy and light 
monoisotopic MS ion ratios for relative quantification of bioac-
tivity (loop peptide) and expression level (control peptide). 
Protein synthesis and enrichment after injury were found to be 
dependent on tissue and turnover of individual proteins. Three 
heavy and light monoisotopic ion ratios for albumin peptides 
from burned mice indicated ~55% enrichment and ~16.7-fold 
downregulation. In contract, serum amyloid P had ~66% 
enrichment and was significantly upregulated. Akt1/PKBα 
had ~56% enrichment and kinase level in response to the burn 
injury was upregulated compared with the control peptide. 
However, kinase bioactivity, represented by the Cys296 peptide, 
was significantly reduced. Overall, we demonstrated that i) 
quantitative proteomics can be performed without completely 
labeled mice; ii) measurement of enrichment of acyl-tRNAs is 
unnecessary and iii) Cys296 plays an important role in kinase 
activity after burn injury.
Introduction
Stable isotope labeling by amino acids in cell culture (SILAC) 
provides relative quantification of in vitro protein synthesis 
and functional proteomics under conditions that mimic disease 
states (1-5). Typically, two cell populations are cultured for 
six doublings times; control cell medium contains the natural 
amino acid (e.g., 
12C6-Lys and/or 
12C6-Arg, 99% natural abun-
dance), and the second medium contains the same levels of 
amino acids with heavy isotopes (e.g., 
13C6-Lys and/or 
13C6-
Arg, 98% abundance) and disease related stimuli. The two cell 
populations are mixed with equal amounts of total protein and 
digested peptides are accurately measured by mass spectrom-
etry with a mass difference of 6 Da for singly charged parent 
ions. Six doubling times allows isotopic enrichment of the 
precursor acyl-tRNA pool to reach ~98% in cancer cell lines. 
Labeling above 95% is generally required for comparative and 
quantitative proteomics by MS. Thus, the relative abundance 
of any paired peptide's monoisotopic MS ion chromatogram 
with SILAC can be used to measure protein synthesis in 
comparison with the controls under in vitro conditions. The 
SILAC approach has been used with C. elegans fed with >98% 
15N-labeled E. coli (6), skeletal muscle from chickens fed with 
a synthetic diet containing 50% of (2H8)-Val (7,8), partially 
labeled rat diet with >99% ape 15N algal cells for 44 days (9) 
and F1-F4 offspring of mice fed with a Lys-free diet containing 
1% of L-13C6-Lys (10). Complete labeling has been reported to 
be achieved by the F2 generation. Metabolic labeling with 15N 
can be performed efficiently and economically, however, data 
interpretation can be challenging since the monoisotopic peak 
can shift, due to the distribution of positional isotopomers as a 
function of labeling time (11,12). Global labeling with 15N has 
been used as a tool for characterization of enrichment under 
partially labeling conditions (13-15). Stable isotope-labeled 
amino acids, such as L-13C6-Lys and L-13C6-Arg, provide ideal 
residues at C-terminal labeling positions for trypsin digestion. 
Protein synthesis depends on 2 factors: acyl-tRNA levels and 
protein turnover rate. These factors are tissue, cell type, time 
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and treatment dependent. To minimize individual variability, 
full incorporation of L-
13C6-Lys can be achieved in mice; 
however, it is very costly.
Analysis of the hypermetabolic/inflammatory response 
under acute phase conditions is very challenging for several 
reasons: i) significant changes in protein expression are associ-
ated with high levels of reactive oxygen species (ROS) and 
post-translational protein modifications (PTM); i.e. not only 
protein levels but also biological activities have to be quan-
tified; ii) individual protein enrichments and incorporated 
isotope distributions may vary with the partially isotope 
enriched precursor t-RNA pool (>50%) and corresponding 
protein turnover rates during the acute phase response.
The metabolic alterations produced by stresses such as 
burn trauma are associated with a hypermetabolic/inflamma-
tory state, that includes: increased protein catabolism (with 
resulting muscle wasting) and insulin resistance. Muscle 
wasting can lead to muscle weakness that can result in 
hypoventilation, prolongation of dependence on mechanical 
ventilation, prolonged rehabilitation and even death (16-19). 
Insulin resistance is a well established state in critically ill 
patients and plays a major role in metabolic derangements. 
Binding of insulin to its receptor (IR) activates the IR tyro-
sine kinase, which then phosphorylates IR substrates (IRSs). 
Phosphorylations of IRS1 and IRS2 transfer the signal from IR 
to phosphatidylinositol-3-kinase (PI3-kinase) (19,20). PTMs 
of the insulin signaling system are considered to be major 
disease-dependent events that regulate glucose transport via 
GLUT-4 translocation and downstream protein synthesis 
(21-27).
Akt1/PKBα is a critical downstream mediator of the IR/
IRS/PI3-kinase pathway of the insulin signaling system 
(28-32). Akt1/PKBα consists of three structural features: the 
N-terminal pleckstrin homology (PH) domain, a large central 
kinase domain and a short C-terminal hydrophobic motif. 
High specific binding of the PH domain with membrane lipid 
products of PI3-kinase recruits Akt1/PKBα to the plasma 
membrane where phosphorylations of Thr
308 (kinase domain) 
and Ser
473 (hydrophobic motif) occur. Phosphorylation of 
Thr
308 partially stimulates kinase activity; however, additional 
phosphorylation of Ser
473 is required for full activity. Akt1/
PKBα activation is associated with a disordered to ordered 
transition of a specific αC helix via an allosteric mechanism. A 
salt bridge between the side-chain of Lys297 and the phosphate 
group of pThr308 in this αC helix contributes to an ordered 
activation segment from DFG292 to APE319 (33-36). Reversible 
dephosphorylations of Thr308 and Ser473 by protein phosphatase 
2A (PP2A) and PH domain leucine-rich repeat protein phos-
phatase (PHLPPα) also occur in the Akt1/PKBα activation/
deactivation cycle (37-40).
In addition to the role of reversible phosphorylation/
dephosphorylation in the regulation of Akt1/PKBα activity, 
this kinase is also reversibly inactivated by S-nitrosylation 
under conditions that result in a persistently increased produc-
tion of NO (28,41-43); such as after burn injury as previously 
reported (44). Thiol titration and NMR data have indicated 
that a disulfide bond (Cys60-Cys77) exists in the kinase PH 
domain (45). A second disulfide bond in the kinase activation 
loop (Cys
297-Cys
311) has been reported to be associated with 
dephosphorylation under oxidative stress in vitro (46). In 
addition, it has been shown that when Cys
224 of Akt1/PKBα 
is mutated to a Ser residue, the kinase becomes resistant to 
NO donor-induced S-nitrosylation and inactivation; suggesting 
that this residue is a major S-nitrosylation acceptor site (43). 
In vivo S-nitrosylations of the insulin receptor (β) and Akt1/
PKBα result to reductions in their kinase activities (42). These 
data suggest that the redox status of Akt1/PKBα, regulated 
by NO, is a second factor in post-translational modifications 
that modulate kinase activity (via dynamic conformational 
changes) and thus GLUT-4 trafficking and protein synthesis.
Recent technical developments have made it feasible to 
study the molecular mechanisms of these important processes 
with quantitative proteomics. These techniques include: i) 
sensitive and site-specific procedures for the detection of 
S-nitrosylation based upon nano-LC interfaced with tandem 
MS/MS methods (47,48); ii) the Biotin-Switch method for 
thiol state discrimination between free, disulfide bonded and 
S-nitrosylated cysteine residues (49-54); problems associ-
ated with quantitative analysis by this technique have been 
discussed previously (48); iii) stable isotope labeling by amino 
acids in mammalians (SILAM) with partially 
15N-labeled rats 
and completely L-
13C6-Lys-labeled mice, and iv) highly specific 
anti-Akt1/PKBα monoclonal antibodies that can be used to 
immunoprecipitate the protein and yield clear SDS-PAGE 
bands with Coomassie Brilliant Blue R-250 staining.
Burn injury impairs IRS1 mediated signaling and attenu-
ated IR-IRS-PI3K-Akt/PKB activation has been the focus of 
research studies at our Institute (22,24,26,28,41,43,44,47,50,57). 
Significantly reduced phosphorylations of Ser
473 and Thr
308, as 
well as Akt/PKB kinase activity were observed under burn 
injury [55% total burn surface area (TBSA) , Day 3] and insulin 
simulation (41). Cys
296 is found to be capable of capturing 
free radicals, such as NO, produced under burn injury (50). 
However, quantification of Cys
296 PTM in the kinase loop 
remains a challenging issue.
To address these considerations and explore the feasibility 
of the basic SILAC approach in animals under acute phase 
and partial isotope labeling conditions, a mouse model with 
full-thickness 40% total burn surface area (TBSA) burn was 
used to proteomically characterize liver Akt1/PKBα from the 
perspectives of both protein expression and biological activity. 
(Isopropyl-
2H7)-L-Leu was selected for labeling based on 4 
considerations: i) L-Leu is an essential amino acid with high 
abundance in proteins. ii) compared with other amino acids, 
(isopropyl-2H7)-L-Leu is relatively inexpensive; iii) none of the 
7 deuterium atoms of (isopropyl-2H7)-L-Leu are attached at the 
α-carbon which may be exchangeable with hydrogen atoms; 
thus in contrast to studies with (2H10)-Leu, MS offset can be 
eliminated as a confounding variable; iv) the hydrophobicity 
of L-Leu reduces false negative discovery during C18 reversed 
phase trapping and desalting.
Materials and methods
Chemicals. Acetonitrile (ACN, LC-MS Chromasolv), formic 
acid (FA), glacial acetic acid, LC-MS grade water, dithioth-
reitol (DTT), (Glu1)-fibrinopeptide B, N,N-dimethylformamide 
(DMF), were obtained from Sigma Chemical Co. (St. Louis, 
MO). SDS-PAGE ready gels (12% Tris-HCl, #161-1102), 
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Blue R-250 (#161-0436) were obtained from Bio-Rad. 
The trypsin profile IGD kit (#PP0100) was obtained from 
Sigma. Anti-Akt1/PKBα monoclonal antibody (cat #05-796, 
Lot #26860) and inactive Akt1/PKBα (cat #14-279) were 
purchased from Upstate (Charlottesville, VA). Immobilized 
monomeric avidin beads were a product of Pierce Chemical 
Co., Rockford, IL (cat #20228). Iodoacetyl-LC-biotin (cat 
#21333) were purchased from Pierce.
Burn injury. Male CD-1 mice (Charles River, Wilmington, 
MA) weighing 25-30 g were used throughout this study. 
The Institutional Animal Care Committee approved the 
study protocol. The animal care facility is accredited by the 
Association for Assessment and Accreditation of Laboratory 
Animal Care. A standardized thermal injury consisting of 
full-thickness scald involving 40% of the body surface area 
was performed on the mice (n=3) using previously described 
methods (55). Briefly, after anesthesia with intraperitoneal 
ketamine (60 mg/kg) and xylazine (1.3 mg/kg), the animals 
were shaven, and placed in a mold on top of a boiling water 
bath for 10 sec, exposing the back to a 40% body surface area 
full-thickness burn injury. Each mouse was given an intraperi-
toneal injection of saline (50 ml/kg) to replace intravascular 
volume known to be lost after thermal injury. Sham-treated 
(n=3, control) mice were anesthetized, confined to the mold 
without burning, dipped in water at room temperature, given 
saline resuscitation, and otherwise treated in the same fashion 
as the injured animals.
The routine protocol for pain management was 72 h of 
scheduled analgesia followed by p.r.n. analgesia based on 
overt signs of distress. This procedure was viewed as adequate 
pain management for this potentially painful procedure. The 
analgesic was buprenorphine (0.05 mg/kg s.c.) and/or a topical 
agent (EMLA cream) until discomfort disappeared. The 
buprenorphine was given 10-15 min prior to burn.
Diets. The diet with depletion of L-Leu was obtained as 
L-amino acids defined diet for rats and mice. (Dyets, Inc., 
Bethlehem, PA; Dyet #510133, meets the 1995 NRC nutrient 
requirements). For producing the light diet, natural L-Leu was 
added to the diet powder (1% by weight) and producing the 
heavy diet, the same amount of (isopropyl-
2H7)-L-Leu was 
added to the diet powder. For both diets, a minimal amount of 
water was added to make biscuits of adequate size. The biscuits 
were dried at room temperature for 1 week as suggested by 
Dyets in order to maintain the original nutrients.
Metabolic labeling with (isopropyl-2H7)-L-Leu and natural 
L-Leu diets. Burned and sham-treated mice were caged sepa-
rately and maintained in a temperature controlled facility with 
a 12-h light/dark cycle. Burned mice were fed with the diet 
containing (isopropyl-
2H7)-L-Leu and sham-treated mice fed 
with the diet containing natural L-Leu. Five grams of light and 
heavy diets were provided daily to each mouse for 7 days. The 
animals had ad libitum access to water.
Blood sampling. The mice were anesthetized with ether inha-
lation, and blood was drawn from the retro-orbital plexus. The 
blood samples were kept on ice and after centrifugation, serum 
samples were frozen in liquid nitrogen and stored at -80˚C.
Tissue homogenization. Equal amounts of tissue from burned 
and sham-treated animals were mixed and homogenized 
in cell lysis buffer (Cell Signaling Technology, cat #9803, 
5 ml/g tissue) containing phenylmethanesulfonyl fluoride 
(BioChemika, 2 mM, freshly prepared 100X stock in ethanol 
just prior to use) on ice with 30 strokes. The homogenates were 
sonicated for 2 min at 4˚C, followed by 3 freeze-thaw cycles in 
liquid nitrogen and 4˚C. The homogenates (5 ml) were extracted 
with chloroform (1 ml) with vortexing for 15 sec and centri-
fuged at 14,000 x g for 2 min. Supernatants were collected 
and re-centrifuged at 14,000 x g for 2 min in order to remove 
traces of chloroform. The final supernatants were diluted with 
PBS to a final volume of 7 ml, and then passed through a 
membrane filter (0.22 µm, Millipore, cat # SLFG025NS). All 
tissue processing was performed at 4˚C.
Immunoprecipitation. Protein G bead slurry (50%, 100 µl) 
was transferred into an Eppendorf vial (1.5 ml), and washed 
2 times with PBS at 4˚C by gently rotating for 1 min. The 
packed beads (50 µl) were collated by centrifuging at 3000 x g 
(5000 rpm) for 20 sec. PBS (50 µl) was added to the beads 
to produce a final immunoprecipitation volume of 100 µl. 
Anti-Akt1 monoclonal antibody (5 µg, Upstate cat #05-796, 
clone AW24) was added and the mixture was gently stirred at 
4˚C for 1 h. Without washing the beads, processed homogenate 
was added and immunoprecipitation was performed for 2 h 
with gently rotating at 4˚C.
Biotinylation. Laemmli sample buffer (50 µl, 2X, pH adjusted 
to 8.0, Bio-Rad, cat #161-0737) was added to the washed 
immunocomplex beads (packed 50 µl, washed with 1 ml PBS 3 
times for 5 min/cycle). This was followed by addition of freshly 
prepared iodoacetyl-LC-biotin solution (10 µl, stock solution; 
2 mg in 1 ml of DMF). Cysteine acylation was performed at 
room temperature for 15 min with stirring. The reaction was 
quenched by addition of 2-mercaptoethanol (5 µl). The beads 
were then heated at 95˚C for 5 min and kept at room tempera-
ture for 30 min prior to loading on SDS-PAGE gels.
SDS-PAGE isolation and in-gel digestion. SDS sample solu-
tion (15 µl) was added to ready gel wells (Bio-Rad, 12% gel, cat 
#161-1102). SDS-PAGE was performed with Tris/Glycine/SDS 
running buffer (Bio-Rad, cat #161-0732) at 200 V for 45 min. The 
gels were removed and washed with deionized water for 5 min 
on a rocking platform and excess water was discarded. Proteins 
were stained with Coomassie Brilliant Blue R-250 for at least 
1 h with gently shaking. The gels were washed three times with 
destaining solution (acetic acid:methanol:dH2O = 10:40:50) for 
2 h. Protein bands were excised as 1x1 mm pieces, and placed 
into siliconized polypropylene Eppendorf tube (1.5 ml). In-gel 
digestion was performed with a Sigma Trypsin Profile IGD kit 
(cat #P0100) according to the manufacturer's protocol.
Avidin purification. Immobilized monomeric avidin beads 
(30 µl, 50% aqueous slurry, Pierce, cat #20228) were placed 
in siliconized polypropylene Eppendorf tubes (0.6 ml), and 
washed with PBS. The digested peptides (70 µl) were added 
to the packed avidin beads (15 µl) and the mixture was placed 
on a rocking platform for 30 min to capture the biotinylated 
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and resuspended in mobile phase A (as described below, 15 µl) 
for control peptide 
252FYGAEIVSALDYLHSEK
268 analysis. 
The beads were then washed with PBS (200 µl x 3), followed 
by ACN/water (10/90 = v/v, 200 µl x 3). The biotinylated 
peptides were recovered by addition of formic acid (30 µl, 
70%) and gently rocking for 5 min at room temperature. This 
recovery step was repeated three time and the supernatants were 
combined, dried via Speed-Vac, and resuspended in mobile 
phase A (15 µl) for biotinylated loop peptide 
290ITDFGLCK
297 
analysis.
LC-MS/MS analysis. All experiments were performed using 
a Waters CapLC-Q-TOF
micro system (Waters Corporation, 
Milford, MA). An analytical column (75 mm ID x 150 mm, 
C18 PepMap300, 5 mm, LC Packings) was used to connect 
the stream select module of the CapLC with the voltage 
supply adapter for ESI. Peptide mixtures were loaded onto the 
precolumn (C18 resin) at a flow rate of 15 µl/min. Dead volume 
from the CapLC injector to the precolumn was measured to be 
~1.5 µl. After washing with mobile phase C (auxiliary pump, 
0.1% formic acid in water/ACN, 2% ACN) for 2 min, the 
trapped peptides were back washed from the precolumn onto 
the analytical column using the 10-position stream switching 
valve. Freshly prepared mobile phases A and C were sonicated 
under vacuum for about 25 min and mobile phase B was treated 
in this way for 5 min. The mobile phases were degassed every 
week, and the CapLC pumps were wet primed for 20 cycles. 
A linear gradient was used to elute the peptide mixture from 
mobile phase A (0.1% FA in water/ACN, 2% ACN) to mobile 
phase B (0.1% FA in ACN). The linear gradient was segmented 
as follows: isocratic elution with 2% B for 3 min, increasing B 
from 10% to 70% (3-40 min) and isocratic 70% B for 5 min. 
Mobile phase B was then reduced to 2% over 2 min. The injector 
syringe (25 µl) was washed with degassed mobile phase A and 
the injection volume was set as full loop mode (10 µl). The 
gradient flow rate was set at 1.5 µl/min before the 16/1 Nanotee 
splitter and the pressure drop from the analytical column was 
about 800 psi. The pressure drop (or the flow splitting ratio) 
was adjusted and maintained with 20 µm ID capillary tubing at 
the waste outlet position of the Nanotee splitter. The gradient 
flow rate was ~95 nl/min. The electrospray voltage was set 
to ~3000 V to obtain an even ESI plume at the beginning 
of the gradient (high water content). As a routine sensitivity 
check, the PicoTip Emitter position and other parameters were 
adjusted to achieve ~45 counts/sec for the capillary tubing 
background peak (m/z 429). Sample cone and extraction cone 
voltages were set at 45 and 3 V, respectively. The instrument 
was operated in a positive ion mode with the electrospray 
source maintained at 90˚C. The instrument was calibrated 
with synthetic human (Glu
1)-fibrinopeptide B (100 fmol/µl in 
ACN/water = 10:90, 0.1% formic acid, v/v) at an infusion rate 
of 1 µl/min in TOF MS/MS mode. The peptide was selected 
at m/z = 785.8 and focused into the collision cell containing 
argon gas at ~3x10
-5 Torr; the collision energy was set at 35 V. 
Instrument resolution for the (Glu
1)-fibrinopeptide B parent 
ion, m/z = 785.84, was found to be 5,250 FWHM. All data were 
acquired and processed using MassLynx 4.1 software. Data-
dependent acquisition (DDA) was set from m/z 630 to 660 
for the biotinylated (doubly charged m/z 639.83) and control 
peptides (triply charged m/z 647.99). Scan time was ~1.9 sec 
and the inter-scan delay was 0.1 sec. MS to MS/MS switch 
criteria were dependent on reporter ion intensity (3 counts/sec) 
and detection window (2.3 Da, charge status). The instrument 
was switched from MS/MS back to MS after 5 sec without 
intensity restriction.
Evaluation of the biotinylated Cys296 site. In contract to the 
highly abundant proteins in serum, biotinylated Cys296 is 
expressed at very low levels after burn injury and site-specific 
pinpointing requires careful evaluation of low S/N spectra. 
Confirmations of the biotinylated Cys296 residue were performed 
by the following three step procedure: i) for parent ion discov-
eries a narrow MS survey scan was used in order to increase 
MS sensitivity. Under these conditions, only a few false posi-
tive ions were observed and these were eliminated manually. 
ii) The positively discovered parent ions were analyzed with 
PepSeq of MassLynx V4.1 software. iii) For the loop peptide, 
with MS/MS scores <35 and S/N ~3, manual interpretations 
of candidate parent ions were performed with the following 
procedure: continuum MS/MS spectra were obtained and the 
upper 80% was centroided in order to obtain the sequence data 
associated with biotinylated y ions with expected mass shifts. 
Table I. Protein enrichment levels on Day 7 after third degree burn of 40% total burn surface area.
  Sequence, (charge state observed)  Enrichments %, (SD)
Albumin 
243LSQTFPNADFAEITK
257, (2)  53 (3.2)
 
559HKPKATAEQLK
669, (2)  57 (3.8)
 
439APQVSTPTLVEAAR
452, (2)  54 (4.1)
Amyloid P component 
66SQSLFSYSVK
75, (2)  66 (4.9)
 
88VGEYSLYIGQSK
99, (2)  65 (4.6)
 
147APPSIVLGQEQDNYGGGFQR
166, (3)  69 (5.2)
Liver Akt1/PKBα 
9EGWLHKR
15, (2)  59 (4.0)
 
184EVIVAKDEVAHTLTENR
200, (3)  56 (2.7)
 
290ITDFGLB
*KEGIKDGATMK
307, (3)  55 (3.3)
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Cysteine residue monoisotopic mass C3H5NOS = 103.01 Da 
was replaced with the iodoacetyl-LC-biotin derivatized adduct 
monoisotopic mass C21H35N5O4S2 = 485.21 Da.
Results and Discussion
The essential issue for any isotope dilution method is to 
precisely characterize the heavy isotope-labeled internal 
standard in terms of atomic and chemical purities. To deter-
mine the relative quantification of liver Akt1/PKBα after burn 
injury, two typical serum acute phase proteins, negative regu-
lated albumin and positive regulated amyloid P component, as 
well as liver Akt1/PKBα were characterized in a preliminary 
study with tissue and blood samples from 3 mice with burn 
injury (40% TBSA). To eliminate possible mathematical and 
biological complexities associated with of multiple isoto-
Figure 1. Schematic overview of the experimental workflow for partial metabolic labeling. Mice with full-thickness burn injury and sham-treated controls were 
maintained on diets containing (isopropyl-
2H7) or natural L-Leu for 7 days. Liver tissue from the 2 groups of animals (n=3) were harvested and homogenized on 
Day 7. The homogenates were sonicated and subjected to 3 freeze-thaw cycles. Hydrophobic components were removed by chloroform extraction. A: corrected 
relative quantification for partially labeled SILAM. The intensity of unlabeled parent ion from burned animals (obtained by enrichment C1) was subtracted 
from the MS ion intensity of the corresponding light peptide after mixing the tissue samples. Unambiguous characterizations of partially metabolically labeled 
liver Akt1/PKBα were achieved with the isotope dilution method and MS/MS sequence information (A2, B2 and C2). Β: relative quantification of liver Akt1/
PKBα after burn injury. A mixture of the exact amounts (2 g each, isotope dilution) of liver from burned (heavy isotope labeled) and sham-treated (light isotope 
labeled) mice was homogenized and immunoprecipitated. The free cysteine residues were acetylated with iodoacetyl-LC-biotin at room temperature for 15 min 
followed by quenching with 2-mercaptoethanol. The beads were then heated at 95˚C for 5 min and kept at room temperature for 30 min prior to SDS-PAGE. 
Biotinylated peptides, including the kinase loop peptide 
290ITDFGLCK
297, were captured with immobilized monomeric avidin beads. The control peptide, 
252FYGAEIVSALDYLHSEK
268 located just outside of the kinase loop (for assessment of kinase protein level after injury) was obtained from supernatant (B1). 
Unambiguous confirmations of the peptides and the expected labelings were obtained from singly charged y ions (B2). C: Akt1/PKBα enrichment determination. 
Akt1/PKBα was immunoprecipitated and free cysteine was biotinylated as described above. Doubly and triply charged tryptic peptides were analyzed with 
nano-LC interfaced with Q-TOFmicro tandem mass spectrometry (C1). Partially labeled parent ions with MS difference of 3.5 Da (doubly charged under ESI) 
were confirmed via their singly charged heavy y ions with MS difference of 7.0 Da (C2). The monoisotopic parent ion ratio of non-labeled (M+2H
+) and labeled 
(M+7+2H
+) peptides represents the metabolic labeling efficiency of one instance of (isopropyl-
2H7)-L-Leu incorporation after burn injury. This is an updated 
proteomic version of classical isotope internal standard characterization.LU et al:  PROTEOMICS OF Akt1/PKBα AFTER BURN INJURY 466
pomer population distributions for individual tryptic peptides 
produced with partial labeling conditions, peptides with 
only one instance of (isopropyl-
2H7)-L-Leu were selected for 
measurement of relative labeling efficiencies. A tryptic peptide 
may be positively charged at its N-terminal α-amine group and 
the side-chain amine group of a Lys residue or the guanido 
group of an Arg residue; thus, a doubly charged parent ion, 
(M+2H
+), may be observed under ESI mass spectrometry. In 
addition, triply charged tryptic parent ions, (M+3H
+), may be 
obtained for peptides containing proline or histidine residues 
or with larger size peptides. Peptides with one instance of 
(isopropyl-
2H7)-L-Leu incorporation yield paired light and 
heavy parent ions with monoisotopic mass ion differences of 
3.5 Da (doubly charged) or 2.3 Da (triply charged) under ESI 
conditions. Charge state dependent DDA allows these multiply 
charged peptides to be focused in the CID chamber under 
charged argon cleavages. The singly charged and predomi-
nated light and heavy MS/MS y ion series from the light and 
heavy parent ions are produced with mass difference of 7 Da. 
This allows unambiguous relative quantification of parent 
ion enrichments from possible false positive discoveries. The 
enrichments of three proteins are shown in Table I.
The negative acute phase protein albumin and the positive 
acute phase protein amyloid P component had enrichments of 
~55 and ~66%, respectively (Table I). The enrichment level 
(56%) of liver Akt1/PKBα was found to be very similar to 
that of albumin. These enrichment values represent ultimate 
(isopropyl-2H7)-L-Leu incorporation in each individual protein 
which can be used as the isotopic correction factor for the light 
and heavy parent ion MS ratio obtained by mixing exactly the 
same weight of labeled and non-labeled liver tissues (Fig. 1). 
The partially labeled SILAM reported here is a combination 
of classical isotope dilution principle and the updated nano-
LC-ESI-Q-TOF approach.
The 
439APQVSTPTLVEAAR
452 albumin light and heavy 
peptides, in response to the burn injury with one instance of 
the Leu residue for relative quantification are shown in Fig. 2. 
MS difference of 3.6 Da for the doubly charged monoisotopic 
MS ions at m/z 720.37 and 723.97 indicates (isopropyl-
2H7)-L-
Leu incorporation into the m/z 723.97 ion from metabolically 
labeled albumin after burn injury. MS/MS analysis confirmed 
that both parent ions have the same sequence and a 7.07 Da shift 
for the y6 ion (from m/z 658.39 to 665.46). The same m/z for the 
y5 ions (VEAAR) under sham (m/z 545.30) and burn conditions 
(m/z 545.31), indicates that, as expected, (isopropyl-
2H7)-L-Leu 
incorporation labeled the y6 ion (LVEAAR). Also, the 54% 
enrichment of albumin (Table I), implies that approximately 
equal amounts of the ion at m/z 723.97 come from burned and 
sham animal sera. Thus, the ion intensity of 2680 under the 
m/z 720.37 peak needs to be subtracted (enrichment correc-
tion) by about the same ion intensity at m/z 723.97, i.e., the 
corrected m/z 720.37 is 2529. The corrected monoisotopic ion 
ratio, m/z 720.37: m/z 723.97 = 16.7, indicates that albumin was 
downregulated by 16.7 fold in the burned animals. In contrast, 
positively regulated amyloid P component reached a higher 
enrichment level of ~66%. Amyloid P component light and heavy 
peptides (66SQSLFSYSVK75) were found at m/z 573.37 (sham) 
and m/z 576.79 (burn) with doubly charged MS difference of 
3.52 Da (Fig. 3). MS/MS data of the parent ion at m/z 576.79 
indicates that the y6 ion (FSYSVK) without labeling occurs at 
m/z 695.47. However, heavy y7 ion (LFSYSVK) at m/z 815.61 
was obtained with a mass increase of 7.02 Da compared with 
the corresponding unlabeled ion at m/z 808.59. The monoiso-
topic MS ion intensity ratio of m/z 573.27: m/z 576.79 = 0.5 
indicated that there was little contribution of the m/z 573.27 
ion from sham-treated mice after mixing equal volumes of 
serums (2 µl). In fact, Coomassie Brilliant Blue R-250 staining 
after SDS-PAGE did not demonstrate an amyloid P component 
Figure 2. Relative quantification of the downregulation of serum albumin. The monoisotopic MS ion difference of 3.6 Da from the doubly charged parent ions 
at m/z 720.37 and 723.97 indicates (isopropyl-
2H7)-L-Leu incorporation into the m/z 723.97 (
439APQVSTPTLVEAAR
452). MS/MS analysis confirmed that both 
ions have the same sequences. The corrected monoisotopic ion ratio, m/z 720.37: m/z 723.97 = 16.7 based on the enrichment listed in Table I, indicates that 
albumin was downregulated by 16.7 fold after burn injury.INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  29:  461-471,  2012 467
band from serum (2 µl) from sham-treated animals. In this case, 
relative quantification failed due to lack of a control peptide; 
suggesting amyloid P component is upregulated significantly 
after the burn injury.
Akt1/PKBα was immunoprecipitated from the mixture of 
(isopropyl-
2H7)-L-leucine-labeled liver from burned mice an 
equal amount tissue from sham-treated animals and processed 
further by the methods described above. The relative expres-
sion of Akt1/PKBα from livers of burned and sham-treated 
mice (Fig. 4). The triply charged monoisotopic parent ion 
at m/z 647.99 was detected for the control peptide 252FYGA 
EIVSALDYLHSEK268; calculated (M+3H+) = 647.99. Two 
heavy monoisotopic parent ions at m/z 650.34 and 652.36 
indicates one and two instances of (isopropyl-
2H7)-L-Leu incor-
Figure 3. Relative quantification of the upregulation of amyloid P component. Amyloid P component light and heavy peptides (
66SQSLFSYSVK
75) were 
identified at m/z 573.27 (sham) and m/z 576.79 (burn) with doubly charged MS difference of 3.52 Da. A monoisotopic MS ion intensity ratio of m/z 573.27: 
m/z 576.79 = 0.5 demonstrated that there is little contribution of the m/z 573.27 from sham mice after mixing equal volumes of serums (2 µl). This suggests 
that amyloid P component is significantly upregulated (undetectable in sham-treated mice).
Figure 4. Changes in liver Akt1/PKBα expression after burn injury. A triply charged monoisotopic parent ion at m/z 647.99 was found for the control peptide 
252FYGAEIVSALDYLHSEK
268; calculated (M+3H
+) = 647.99. Two heavy monoisotopic parent ions at m/z 650.34 and 652.36 indicate one and two instances 
of (isopropyl-2H7)-L-Leu incorporation into the control peptide. Akt1/PKBα protein expression, estimated from both heavy ions, was found to be upregulated 
after correction for both enrichment and background.LU et al:  PROTEOMICS OF Akt1/PKBα AFTER BURN INJURY 468
poration into the control peptide. Triply charged MS differences 
were found to be 2.3 Da (calculated MS difference for one 
heavy Leu incorporation: 7/3=2.3 Da) and 4.3 Da (calculated 
MS difference for two heavy Leu incorporation: 14/3=4.6 Da), 
respectively. MS/MS y ion series (from y3 to y12 as shown 
in Fig. 5) of the m/z 647.98 confirms the control peptide for 
studying protein expression. The intensities of the m/z 650.34 
and 652.36 ions represent the heavy Akt1/PKBα populations 
from burn injured mice, whereas the m/z 647.99 ion is derived 
from the sham-treated animals. Estimated total ion intensity 
was ~9.5 after burn injury and ~6.5 after sham treatment. Due 
to the low S/N of ~2 for the heavy ions and the enrichment of 
56% in Table I, Akt1/PKBα protein expression, was observed 
to be upregulated in response to burn injury the mice. However, 
the heavy ion for the biotinylated peptide, 
290ITDFGLCK
297, 
which was used as a marker for kinase activity, was signifi-
cantly reduced (almost to background) after injury (Fig. 6). 
The biotinylated light peptides 290ITDFGLCK297 of Akt1/
PKBα from sham-treated mice was detected at m/z 639.88 
and was doubly charged as indicated by the natural abundance 
carbon isotope peak at m/z 640.33. Three biotinylated y2, y4 
and y6 ions at m/z 632.44, 802.51 and 1064.59 confirmed the 
loop peptide sequence with biotin modification (Fig. 7). The 
corresponding y2 ion of iodoacetyl-LC-biotin derivatized, 
296CK
297, was confirmed at m/z 632.44 (expected m/z 632.33 
equal to 485.21 + 145.10 + 2.02). DDA with low S/N occurred 
in vivo studies was performed with a continuum mode to 
enhance the parent ion discovery. On the other hand, centroided 
spectra are found to be necessary to obtain accurately the diag-
nostic modifications in the y ions. 
The biotinylated heavy peptide 290ITDFGLCK297 in Akt1/
PKBα from burn injured mice (n=3) was identified at m/z 643.38 
with its natural carbon isotopic peak at m/z 643.88. An MS 
difference of 3.5 Da between the paired light and heavy parent 
ions clearly indicated that one instance of (isopropyl-
2H7)-L-
Leu was incorporation into the doubly charged parent ion at 
m/z 643.38 with doubly charged state (n=3). MS ion intensity 
at m/z 643.38 indicated that loop peptide containing Cys
296 was 
almost undetectable after burn injury. These observations were 
evaluated with MS/MS sequencing; peptide charge status and 
MS shift of the isotope-labeled paired peptides in vivo.
The incorporation efficiencies of isotopically labeled 
peptides in Table  I demonstrates that amyloid P component 
was 10% higher than albumin; suggesting a faster turnover 
rate during upregulation. Serum albumin and liver Akt1/
PKBα appear to have similar enrichments ~55%. Classically, 
individual protein fractional synthesis rate (FRS) is calculated 
by the relative isotope enrichment ratio of the labeled protein 
vs. precursor acyl-tRNA over the labeling time period for a 
given isotope tracer (56,57). FSR is a very important parameter 
for assessing effects of clinical interventions by comparisons 
between patients and healthy controls. In general, informa-
tion about protein synthesis obtained with FRS and partially 
labeled SILAM are very similar and either can be used to 
optimize therapeutic strategies.
Our previous studies with thermally injured rats have 
demonstrated that there is no apparent alteration in binding 
of insulin to its receptors in liver, skeletal muscle or adipose 
tissue (22). Thus, acute and chronic insulin resistances induced 
by surgical trauma, burn injury, hemorrhage and sepsis are 
primarily post-receptor effects in the insulin-like growth 
factor/PI3-kinase/Akt pathway. Phosphorylations of specific 
Ser and Thr residues in the C-terminus of insulin receptor 
substrate-1 (IRS-1) induces its degradation via the ubiquitin-
proteasome pathway (unpublished data); which may be an early 
biological effect after receptor binding. Impaired Akt1/PKBα 
kinase activity after injury may be a later downstream event. 
Deficiency of Akt1/PKBα causes decreased somatic cell and 
body size (58), while knockout of Akt2/PKBα leads to insulin 
resistance (59). Akt1/PKBα is involved in cellular survival 
Figure 5. MS/MS sequencing of control peptides. MS/MS y ion series of the m/z 647.98 ion confirms the control peptide for studying protein expression.INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  29:  461-471,  2012 469
pathways, by inhibiting apoptotic processes and stimulating 
protein synthesis pathways. It is also a key signaling protein 
in cellular pathways of skeletal muscle differentiation (60,61). 
Currently, assays of Akt1/PKBα activity in vitro and in vivo 
are performed with antibodies specific for the phosphorylated 
Ser473 and Thr308 residues which are critical for stabilizing the 
global and loop active conformations of the kinase. Difficulties 
with using anti-phospho-Ser, but not anti-phospho-Tyr anti-
bodies, have occurred in our phosphoproteomic research 
(unpublished data). NO production is elevated after burn 
Figure 7. MS/MS sequencing of the kinase loop peptide. MS/MS spectra were smoothed and the upper 80% centroided to obtain sequence data in the cases of 
very low S/N. Three biotinylated y2, y4 and y6 ions at m/z 632.44, 802.51 and 1064.59 unambiguously confirmed the loop peptide sequence with biotinylated 
mass shifts for kinase bioactivity measurements.
Figure 6. Liver Akt1/PKBα activity measurement via the loop peptide. Light peptide, 
290ITDFGLCK
297, of Akt1/PKBα from sham-treated mice were detected 
at m/z 639.88; doubly charged as indicated by the natural abundance carbon isotope peak at m/z 640.33. Biotinylated heavy peptides 290ITDFGLCK297 of Akt1/
PKBα from the burn injured mice were detected at m/z 643.38; doubly charged as indicated by the natural abundance carbon isotope peak at m/z 643.88. The 
MS difference of 3.5 Da between the paired light and heavy parent ions indicates one instance of (isopropyl-
2H7)-L-Leu incorporation into the heavy ion at 
m/z 643.38 after burn injury. The intensity of the m/z 643.38 ion indicates that the loop peptide containing Cys
296 was markedly reduced (almost to baseline) 
in response to burn injury (n=3).LU et al:  PROTEOMICS OF Akt1/PKBα AFTER BURN INJURY 470
injury and in patients with type 2 diabetic (61,63) and it has 
been shown that the Cys
297-Cys
311 disulfide bond in the kinase 
loop may be formed in association with dephosphorylation 
under oxidative stress in vitro (46). Reversible S-nitrosylation 
at Cys
296 in the kinase loop is another PTM which comple-
ments reversible phosphorylation at Thr
308 in the regulation 
of kinase activity (37). It has been shown that Akt1/PKBα 
undergoes transient phosphorylation/dephosphorylation which 
regulates the kinase active conformation cycle (37); kinase 
disulfide bond formation, Cys
297-Cys
311, and dephosphoryla-
tion at pThr
308 are induced simultaneously by H2O2 oxidative 
stress in vitro (46); and high levels of nitric oxide production 
occurs in both burn injured rats (62) and diabetic patients (63). 
The free thiol group of Cys
296 undergoes loop conformational 
changes by capture of nitric oxide, or chemical modifications 
with other reactive oxygen species produced under the burn 
injury; thus blocking substrate recognition. Intact loop peptide 
with a trace amount of free cysteine in the peptide popula-
tion, 
290ITDFGLCK
297, after burn injury was developed as 
an unambiguous index for bioactivity. However, this peptide 
is not related to kinase protein expression in responses to the 
burn, since varying degrees of different thiol modifications in 
the loop may occur at the same time. In contrast, the control 
peptide, 
252FYGAEIVSALDYLHSEK
268, located just outside 
of the kinase loop, was a useful index of protein level. 
Kinase bioactivity measured with the tandem MS was 
comparable with previously reported data measured with 
immune complex kinase assay and anti-pThr
308 as well as anti-
Ser
437 monoclonal antibodies (41), whereas protein levels were 
slightly increased in responses to injury. MS/MS sequence 
analysis and (isopropyl-
2H7)-L-Leu incorporation in the paired 
peptides indicated that after thermal injury kinase activity is 
significantly reduced, despite increased protein expression.
Overall, our findings indicate that neither complete labeling 
of nor measurement of acyl-tRNA enrichment are necessary 
or critical for quantitative proteomics with SILAM. Cys
296 
thiol state is considered as one of the important factors for 
the kinase activity. The limitations of partially labeled SILAM 
for clinical studies are first that specific protein enrichment 
must be measured in tissues labeled with heavy isotopes under 
stress conditions; unfortunately, many proteins of clinical 
interest occur at low abundance and thus there is a high rate 
of false negative discovery. Second, sequence confirmation of 
individual proteins requires that SDS-PAGE bands be visible 
by Coomassie Brilliant Blue R-250 staining (at least 0.1 µg). 
Despite these limitations our observations may provide new 
insights into the treatment of muscle wasting and other aspects 
of insulin resistance after critical injury.
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